In his article, Dr. Narain explores how biology-first AI is transforming the future of drug development, not just in discovery, but especially in clinical trials, and why regulatory momentum is finally catching up.
As he writes:
“From using AI-based computational modeling to phase out animal testing for monoclonal antibodies, to deploying its proprietary large language model-powered tool, Elsa, to read, write, and summarize regulatory documents—reducing review time from three days to just six minutes—the FDA is sending a powerful signal: AI is no longer a futuristic concept in drug development. It is a real and necessary tool to address the unsustainable costs, high attrition rates, and long timelines that have plagued R&D for decades.”
Read the full article: DDW: Biology-First AI Is Redefining Success In Drug Development (p48-49)
At BPGbio, we’ve built our platform—NAi Interrogative Biology—on the foundation of causal, Bayesian AI, helping to guide smarter trial designs, refine patient selection, and accelerate development with greater precision and safety.
